p53 codon 72 increased biochemical recurrence risk after radical prostatectomy in a southern Chinese population.
BACKGROUND
Alterations in P53 and murine double minute 2 (MDM2) genes appear to be important in the development of many human tumors. We investigated the potential prognostic roles of p53 codon 72 and MDM2 309 and 1797 polymorphisms in prostate cancer after radical prostatectomy.


METHODS
Fifty southern Chinese with prostate cancer undergoing radical prostatectomy were included in this study. All polymorphisms were detected by PCR-RFLP. Their prognosis on biochemical recurrence was assessed using Kaplan-Meier analysis and Cox regression model.


RESULTS
p53 codon 72 GG genotype was associated with increased biochemical recurrence compared with CG+CC genotypes and poorer PSA-free survival. It was also noted that GG genotype was an independent risk factor for biochemical recurrence after radical prostatectomy on multivariate analysis. No statistical difference was observed in MDM2 polymorphisms and prostate cancer prognosis.


CONCLUSIONS
Our data revealed that p53 codon 72 GG genotype carriers more frequently show biochemical recurrence than CG+CC genotypes carriers.
Xu
Bin
B
Department of Urology, First Affiliated Hospital of Nanjing Medical University, Nanjing, China.
Mi
Yuan-Yuan
YY
Min
Zhi-Chao
ZC
Cheng
Gong
G
Tong
Na
N
Tao
Jun
J
Li
Peng-Chao
PC
Wang
Mei-Lin
ML
Tang
Jia-Lin
JL
Zhang
Zheng-Dong
ZD
Song
Ning-Hong
NH
Zhang
Wei
W
Wu
Hong-Fei
HF
Feng
Ning-Han
NH
Hua
Li-Xin
LX
D000368:Aged; D044466:Asian People / Q000235:genetics*; D016009:Chi-Square Distribution; D002681:China; D003062:Codon; D018572:Disease-Free Survival; D005787:Gene Frequency; D020022:Genetic Predisposition to Disease; D006801:Humans; D053208:Kaplan-Meier Estimate; D008297:Male; D009364:Neoplasm Recurrence, Local / Q000208:ethnology / Q000235:genetics*; D009367:Neoplasm Staging; D010641:Phenotype; D010865:Pilot Projects; D020641:Polymorphism, Single Nucleotide; D016016:Proportional Hazards Models; D017430:Prostate-Specific Antigen / Q000097:blood; D011468:Prostatectomy; D011471:Prostatic Neoplasms / Q000208:ethnology / Q000235:genetics* / Q000601:surgery*; D051736:Proto-Oncogene Proteins c-mdm2 / Q000235:genetics; D018570:Risk Assessment; D012307:Risk Factors; D016896:Treatment Outcome; D016159:Tumor Suppressor Protein p53 / Q000235:genetics*
D003062:Codon; C495901:TP53 protein, human; D016159:Tumor Suppressor Protein p53; C497206:MDM2 protein, human; D051736:Proto-Oncogene Proteins c-mdm2; D017430:Prostate-Specific Antigen